Letrozole Arrow

Letrozole, the active ingredient in Letrozole Arrow, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, including adjuvant and metastatic settings.

GNH USA supplies Letrozole Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Letrozole is used in hormone‑driven breast cancer pathways to lower estrogen production.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor proliferation by decreasing circulating estrogen. - Adjuvant treatment of early‑stage breast cancer: helps prevent disease recurrence after surgery. - Metastatic breast cancer: provides disease control when cancer has spread beyond the breast.

Letrozole may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hot flashes - Joint or muscle pain - Fatigue - Nausea - Headache

Serious or Rare Side Effects: - Severe bone loss leading to fractures - Liver function abnormalities - Allergic reactions such as rash or angioedema

When prescribing Letrozole, clinicians should consider several safety measures and monitoring requirements. - Pregnancy avoidance: contraindicated in pregnancy (Category X) due to risk of fetal harm. - Bone health monitoring: assess bone mineral density periodically because estrogen depletion can accelerate osteoporosis. - Cardiovascular risk: evaluate lipid profile and blood pressure as estrogen reduction may affect cardiovascular status. - Liver function: check hepatic enzymes before initiation and during therapy. - Drug interactions: review concomitant medications for potential CYP2A6 or CYP3A4 interactions. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Letrozole can affect the metabolism of other medicines and may be influenced by co‑administered drugs.

Major Interactions (Avoid): - Strong CYP2A6 inducers (e.g., rifampicin): may markedly reduce letrozole exposure. - Concurrent use with estrogen‑containing hormone therapy: antagonizes therapeutic intent.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma levels. - Anticoagulants (e.g., warfarin): potential alteration of INR, requiring monitoring. - Tamoxifen: may interfere with aromatase inhibition efficacy. - SSRIs that affect estrogen metabolism: monitor for enhanced side effects.